182 results about "HDAC inhibitor" patented technology

The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and / or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.

The invention discloses a hydroxamic acid double-target compound derivative and application thereof. The double-target derivative designed by the invention has obvious inhibitory activity on WDR5 protein and HDAC protein, can be used as a WDR5 and HDAC double-target inhibitor, is used for treating diseases related to WDR5 and HDAC, and aims at improving the treatment effect of the existing HDAC inhibitor. The micromolecule shows good activity in various experiments, and is expected to be developed into a specific antitumor drug.

A combination of an immune cell and a benzamide HDAC inhibitor, the immune cell expressing a receptor that recognizes a tumor antigen. In addition, a test kit comprising the immune cell and the benzamide HDAC inhibitor and a method of combination therapy for cancer and other diseases.

Factors that induce in vitro totipotent stem cells that are functionally and molecularly similar to totipotent embryonic cells are provided. Provided are a cell culture medium composition for inducing cell totipotency of an isolated cell in vitro and an isolated chemically induced full potential stem cell (ciTPSC) obtained using the same. The composition includes a totipotent chemical inducer (CDT) from each of the following groups in an amount effective to induce untreated cells to be fully potential stem cells (TPS): (1) an HDAC inhibitor, (2) a Dot1L inhibitor, (3) a RAR [gamma] agonist, and (4) optionally, a GSK inhibitor. The ciTPSC may be used, for example, in cell therapy and tissue engineering.

The invention belongs to the field of biological medicine, and relates to application of an HDAC (histone deacetylase) inhibitor in treatment of liver cancer, in particular to application of the HDAC inhibitor in preparation of medicines for treating liver cancer, slowing down liver cancer progress and / or preventing liver cancer recurrence, a medicine composition for treating liver cancer, slowing down liver cancer progress and / or preventing liver cancer recurrence and a treatment method.

The invention belongs to the field of medical chemistry, and particularly discloses an HDAC (histone deacetylase) inhibitor containing a sulfinyl iminobenzamide structure, and the HDAC inhibitor is a compound as shown in a general formula (I) or a pharmaceutically acceptable salt thereof. The invention also discloses a pharmaceutical composition containing the HDAC inhibitor, and the HDAC inhibitor is used for treating cancers and diseases related to neurodegeneration. The HDAC inhibitor prepared by the preparation method disclosed by the invention has surprisingly better HDAC1 enzyme inhibition activity and excellent HDAC1 / 3 selectivity, and has better enzyme inhibition activity on a CoREST compound. # imgabs0 #

The invention provides an application of a histone deacetylase (HDAC) inhibitor and / or a JAK2 inhibitor in inducing hematopoietic stem progenitor cells, mononuclear cells or total nucleated cells to generate megakaryocytes and / or megakaryocyte progenitor cells. The invention also provides methods of inducing hematopoietic stem progenitor cells, mononuclear cells or total nucleated cells to produce megakaryocytes and / or megakaryocyte progenitor cells comprising exposing the cells to an HDAC inhibitor, and / or exposing the cells to a JAK2 inhibitor.

The present invention provides a method of treating or preventing a medical condition associated with herpes virus infection comprising administering a therapeutically effective amount of an immune cell comprising a chimeric antigen receptor (CAR) on its cell surface and an HDAC inhibitor. Kits and pharmaceutical products comprising an HDAC inhibitor and CAR-containing immune cells are also provided. In addition, an antibody that binds to gp350 of Epstein-Barr virus present on the cell surface of a target cell is provided.

The present invention belongs to the technical field of medicines. The present invention relates to an imidazolidinedione HDAC inhibitor, and a preparation method therefor and the use thereof. Provided in the present invention is an imidazolidinedione HDAC inhibitor, which inhibitor is a substituted imidazolidinedione compound as represented by general formula V, or a stereoisomer, a hydrate or a pharmaceutically acceptable salt thereof. The inhibitor has efficient and good HDAC enzyme inhibitory activity, and also has good in-vitro anti-tumor activity. The inhibitor provides a new way for the application of an HDAC inhibitor in tumors / or the treatment of diseases related to uncontrolled histone deacetylase activity.

Provided herein are methods of treating a trauma patient, the method including: (a) administering a HDAC inhibitor to the trauma patient; and (b) administering a GRK2 inhibitor to the trauma patient, wherein the treatment prevents, reduces, or ameliorates the risk of an infection occurring after a traumatic event. In some cases, the infection is a respiratory infection, such as pneumonia. The HDAC inhibitor and / or the GRK2 inhibitor can be administered to the patient before, after, or before and after the traumatic event.

A combination of an immune cell that expresses a receptor that recognizes a tumor antigen and a benzamide-based HDAC inhibitor. The invention further discloses a kit containing the immune cells and the benzamide HDAC inhibitor and a method for combined treatment of diseases such as cancer.

The present application relates to a method for inducing pluripotent cells to proliferate and / or differentiate into megakaryocyte progenitor cells (MKPs), comprising adding a human platelet lysate (hPL) and an HDAC inhibitor to an MKP differentiation medium. The present application also provides a culture medium used in the method, and a composition comprising the culture medium.

The present invention relates to an expansion culture method for natural killer cells and, more particularly, to an expansion culture method for natural killer cells, wherein the cultured natural killer cells are treated with an HDAC inhibitor. According to the present invention, when natural killer cells are subjected to in vitro expansion culture, the cells can be restrained from undergoing cell death, resulting in a remarkable improvement in the viability and production yield of the cells. Thus, natural killer cells, which are needed for cell therapy, such as cancer therapy, etc., can be obtained effectively.

The invention discloses an MEK / HDAC double-target inhibitor as well as a synthesis method and application thereof, and belongs to the technical field of medicines. Through molecular docking and in-vitro thermodynamic migration experiments, the applicant finds that the inhibitor not only can stabilize MEK and HDAC proteins, but also can be specifically combined with the MEK and HDAC proteins in an intracellular environment; protein immunoblotting experiments find that the inhibitor can inhibit reactivation of ERK, overcomes the limitation of a single-target inhibitor in curative effect and activity, and significantly improves the drug resistance problem of trametinib in ovarian cancer treatment and various EGFR-TKI treatment in non-small cell lung cancer treatment; furthermore, an in-vitro anti-tumor activity experiment shows that the IC50 value of the MEK / HDAC inhibitor on tumor cells from human ovarian cancer and various lung cancers is 0.07-10 mu M, and the MEK / HDAC inhibitor has a wide and remarkable proliferation inhibition effect.

The present disclosure generally relates to novel multiple target inhibitor of tyrosine kinases (TKs) which can suppress angiogenesis, metastasis, oncogenesis, and / or immune regulation activities by inhibiting TKs and have very potent immunomodulatory activity. The present disclosure also relates to a method of using the tyrosine kinase inhibitors, alone or in combination with HDAC inhibitor, for the treatment of cancers, in particular in cancer immunotherapy, by regulating the tumor microenvironment, including reducing tumor hypoxia, reducing lactic acid accumulation, activating CTL, inhibiting the number and activity of immunosuppressive cells, finally obtaining superior anti-cancer benefits and / or producing lasting immune memory.

The present disclosure generally relates to compounds of formula (I) which are multiple target inhibitors of tyrosine kinases (TKs) and which can suppress angiogenesis, metastasis, oncogenesis, and / or immune regulation activities by inhibiting TKs and have very potent immunomodulatory activity. The present disclosure also relates to a method of using said tyrosine kinase inhibitors, alone or in combination with HDAC inhibitor, for the treatment of cancers, in particular in cancer immunotherapy, by regulating the tumor microenvironment, including reducing tumor hypoxia, reducing lactic acid accumulation, activating CTL, inhibiting the number and activity of immunosuppressive cells, finally obtaining superior anti-cancer benefits and / or producing lasting immune memory.

A method for reprogramming native CD4+ T-cells is provided. The method comprises incubating the CD4+ T-cells with a Class 1 HDAC inhibitor for a period of time sufficient to increase cytotoxicity of the CD4+ T-cells in comparison to the cytotoxicity of native CD4+ T-cells. The method may be utilized to prepare cytotoxic tumor infiltrating CD4+ T-cells for use to treat cancer, including MHC-I deficient cancers.

This invention belongs to the field of pharmaceutical preparation technology, specifically relating to an HDAC inhibitor based on a tyrosine backbone, its synthesis method, and its application. The invention uses L-tyrosine as the backbone, with its aromatic ring as the Cap region, linked by a flexible alkyl chain via an ether bond, and terminated by an isohydroxamic acid group (ZBG). The tyrosine backbone provides a rigid structure, reducing entropy loss and enhancing hydrophobic interactions with the HDAC surface. By introducing substituents (such as halogens, methyl groups, etc.) onto the tyrosine benzene ring, the affinity with the HDAC active pocket is further optimized. The prepared compound b19 exhibits an HDAC inhibition capacity of 100%. 50 The concentration reached 26.8 nM, exhibiting superior antitumor activity compared to SAHA, especially against solid tumors such as HeLa cells with IC50. 50 It is 0.55 μM.

Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-PD-1 or an anti-PD-L1 antibody.

The present disclosure relates to first-in-class dual CYP17A1-HDAC inhibitors, process of preparing the same and uses thereof in treatment of diseases / disorders mediated by CYP17A1, HDAC and / or both, in particular cancer (e.g., glioblastoma or prostate cancer).

The present application relates to a method for inducing proliferation and / or differentiation of pluripotent cells into megakaryocyte progenitor cells (MKP), comprising adding human platelet lysate (hPL) and an HDAC inhibitor to an MKP differentiation medium. The invention also provides a culture medium used by the method and a composition containing the culture medium.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

The disclosure relates to crystalline forms of an HDAC inhibitor, pharmaceutical compositions thereof, and methods of treating cancers, including cancers having modified STK11 activity or expression, by administering an effective amount of the crystalline forms or compositions.

A method for treating Ewing's sarcoma in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of (E)-3-(2-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)pyrimidin-5-yl)-N-hydroxyacrylamide or a pharmaceutically acceptable salt thereof.

The disclosure, in one aspect, relates to methods for treating cancer in a subject, the methods including at least the steps of administering at least one drug from each of at least two classes selected from an inhibitor of poly-ADP ribose polymerase (PARP inhibitor), an inhibitor of DNA-dependent protein kinase catalytic subunit (DNA-PKcs inhibitor), an inhibitor of wild-type isocitrate dehydrogenase (IDH inhibitor), an inhibitor of histone acetyltransferase (HAT inhibitor), an inhibitor of histone deacetylase (HDAC inhibitor), an inhibitor of DNA polymerase Θ (POLΘ inhibitor), an inhibitor of platelet-derived growth factor receptor (PDGFR inhibitor), and a DNA alkylating agent to the subject. In any of these aspects, the disclosed method allows for administering lower doses of the drugs in combination compared to administration as single drugs while preventing the recurrence of the cancer, preventing drug resistance of the cancer, and reducing side effects associated with cancer treatment.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

Provided is a method of differentiating human pluripotent stem cells (hPSCs) into mature pancreatic β cells, comprising contacting hPSC-derived, differentiated immature pancreatic β cells with a histone deacetylase (HDAC) inhibitor.